ciprofloxacin has been researched along with Pneumococcal Infections in 69 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Pneumococcal Infections: Infections with bacteria of the species STREPTOCOCCUS PNEUMONIAE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Moxifloxacin has potent bactericidal activity against Streptococcus pneumoniae; a major causative organism of lower respiratory tract infections." | 7.80 | Moxifloxacin in lower respiratory tract infections: in silico simulation of different bacterial resistance and drug exposure scenarios. ( Noreddin, AM; Salem, AH, 2014) |
| "To test whether intranasal ciprofloxacin/dexamethasone or dexamethasone alone affects the course of acute bacterial rhinosinusitis in mice." | 7.74 | Effect of topical ciprofloxacin/dexamethasone or dexamethasone alone on acute Streptococcus pneumoniae rhinosinusitis in mice. ( Baroody, F; Markaryan, A; Naclerio, R; Sahin-Yilmaz, A; Thompson, K; Wall, GM, 2008) |
| "A dose-decreasing immunocompetent sepsis mouse model was used to evaluate the in vivo effect of levofloxacin, moxifloxacin and gemifloxacin, using a ciprofloxacin/levofloxacin susceptible serotype 6B strain (ciprofloxacin MIC: 1 mg/l) and two resistant serotype 14 and 19F strains with gyrA and parC point mutations (ciprofloxacin MICs of 32 and 64 mg/l, respectively)." | 7.73 | In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point. ( Aguilar, L; Alkorta, M; Giménez, MJ; Pérez-Trallero, E; Vicente, D, 2005) |
| "Eighty hospital patients with acute purulent exacerbations of chronic bronchitis associated with Haemophilus influenzae, Streptococcus pneumoniae, Branhamella catarrhalis or Pseudomonas aeruginosa were treated with ciprofloxacin." | 7.67 | Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis. ( Baur, C; Davies, BI; Maesen, FP, 1986) |
| "Thirty four patients with acute purulent exacerbations of chronic bronchitis were treated with 500 mg ciprofloxacin twice daily, orally, for ten days." | 7.67 | Treatment of acute exacerbations of chronic bronchitis with ciprofloxacin. ( Hoogkamp-Korstanje, JA; Klein, SJ, 1987) |
| "Moxifloxacin has potent bactericidal activity against Streptococcus pneumoniae; a major causative organism of lower respiratory tract infections." | 3.80 | Moxifloxacin in lower respiratory tract infections: in silico simulation of different bacterial resistance and drug exposure scenarios. ( Noreddin, AM; Salem, AH, 2014) |
| "To test whether intranasal ciprofloxacin/dexamethasone or dexamethasone alone affects the course of acute bacterial rhinosinusitis in mice." | 3.74 | Effect of topical ciprofloxacin/dexamethasone or dexamethasone alone on acute Streptococcus pneumoniae rhinosinusitis in mice. ( Baroody, F; Markaryan, A; Naclerio, R; Sahin-Yilmaz, A; Thompson, K; Wall, GM, 2008) |
| "A dose-decreasing immunocompetent sepsis mouse model was used to evaluate the in vivo effect of levofloxacin, moxifloxacin and gemifloxacin, using a ciprofloxacin/levofloxacin susceptible serotype 6B strain (ciprofloxacin MIC: 1 mg/l) and two resistant serotype 14 and 19F strains with gyrA and parC point mutations (ciprofloxacin MICs of 32 and 64 mg/l, respectively)." | 3.73 | In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point. ( Aguilar, L; Alkorta, M; Giménez, MJ; Pérez-Trallero, E; Vicente, D, 2005) |
| "Eighty hospital patients with acute purulent exacerbations of chronic bronchitis associated with Haemophilus influenzae, Streptococcus pneumoniae, Branhamella catarrhalis or Pseudomonas aeruginosa were treated with ciprofloxacin." | 3.67 | Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis. ( Baur, C; Davies, BI; Maesen, FP, 1986) |
| "Thirty four patients with acute purulent exacerbations of chronic bronchitis were treated with 500 mg ciprofloxacin twice daily, orally, for ten days." | 3.67 | Treatment of acute exacerbations of chronic bronchitis with ciprofloxacin. ( Hoogkamp-Korstanje, JA; Klein, SJ, 1987) |
| "Pneumoniae." | 2.41 | Pneumococcal septic arthritis of the shoulder. Case report and literature review. ( Avallone, F; Bertone, C; Maniscalco, P; Rivera, F; Urgelli, S, 2002) |
| "In a previous study, levofloxacin 750 mg eradicated 4 ciprofloxacin-resistant isolates of Streptococcus pneumoniae from an in vitro pharmacodynamic model (IVPM)." | 1.35 | Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant Streptococcus pneumoniae. ( Lister, PD, 2008) |
| "Ciprofloxacin resistance was greatest in people >64 years of age and least in those <16 years of age." | 1.34 | Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005. ( Adam, HJ; Baudry, TJ; Hoban, CJ; Hoban, DJ; Laing, NM; Nichol, KA; Schurek, KN; Zhanel, GG, 2007) |
| "Pneumococcal cellulitis is an uncommon infection." | 1.34 | [Streptococcus pneumoniae cellulitis in a diabetic patient]. ( Bouzat, P; Broux, C; Croizé, J; Jacquot, C; Pavese, P; Soriano, E; Stahl, JP, 2007) |
| "The ciprofloxacin MICs were >or=4 microg/ml for six (0." | 1.32 | Telithromycin- and fluoroquinolone-resistant Streptococcus pneumoniae in Taiwan with high prevalence of resistance to macrolides and beta-lactams: SMART program 2001 data. ( Chang, FY; Chuang, YC; Hsueh, PR; Huang, WK; Ko, WC; Lau, YJ; Lee, CM; Leu, HS; Liu, CY; Liu, YC; Lu, JJ; Luh, KT; Shyr, JM; Teng, LJ; Wan, JH; Wu, JJ; Wu, TL; Yan, JJ; Yang, D; Yang, YC, 2003) |
| "Ciprofloxacin was less effective than the levofloxacin regimens against all four study isolates." | 1.32 | Comparative antimicrobial activity of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. ( Garrison, MW, 2003) |
| "The fibrin clots were suspended into the models and removed, in triplicate, at various time points over 48 h." | 1.31 | Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model. ( Hershberger, E; Rybak, MJ, 2000) |
| "An in vitro pharmacodynamic model was used to compare bacterial killing and the development of resistant mutants in the presence of respiratory fluoroquinolones and ciprofloxacin." | 1.31 | In vitro pharmacodynamic modelling simulating free serum concentrations of fluoroquinolones against multidrug-resistant Streptococcus pneumoniae. ( Hoban, DJ; Laing, N; Walters, M; Zhanel, GG, 2001) |
| "Levofloxacin was also quite active, inhibiting 98-100% of the isolates at concentrations < or = 2 micrograms/ml." | 1.30 | Comparative antistreptococcal activity of two newer fluoroquinolones, levofloxacin and sparfloxacin. ( Jones, RN; Pfaller, MA, 1997) |
| "This has implications for the future treatment of pneumococcal infections in this country and emphasizes the need for new anti-pneumococcal agents." | 1.30 | Pneumococcal resistance in the UK. ( Goldsmith, CE; Moore, JE; Murphy, PG, 1997) |
| " In this study, the bactericidal characteristics and pharmacodynamic profiles of levofloxacin, ciprofloxacin, and ampicillin against four isolates of S." | 1.30 | Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. ( Lacy, MK; Lu, W; Nicolau, DP; Nightingale, CH; Quintiliani, R; Tessier, PR; Xu, X, 1999) |
| "Moxifloxacin was effective against all the penicillin-resistant isolates tested, with an MIC of 0." | 1.30 | Comparative in-vitro activity of moxifloxacin, penicillin, ceftriaxone and ciprofloxacin against pneumococci isolated from meningitis. ( Bianco, G; Capone, A; Cassone, M; Tarasi, A; Tarasi, D; Venditti, M, 1999) |
| " The dosing regimen of each drug that yielded serum levels in mice which mimic human therapeutic concentrations of the drugs, were designed." | 1.30 | Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia. ( Bui, KQ; Nicolau, DP; Nightingale, CH; Onyeji, CO; Owens, RC; Quintiliani, R, 1999) |
| "Trovafloxacin is a new fluoroquinolone that has potent microbiological activity against the pneumococcus, including penicillin-resistant strains." | 1.30 | Protective effect of trovafloxacin, ciprofloxacin and ampicillin against Streptococcus pneumoniae in a murine sepsis model. ( Banevicius, MA; Lacy, MK; Nicolau, DP; Nightingale, CH; Quintiliani, R, 1999) |
| "Grepafloxacin MICs >4 mg/L were associated with this GyrA mutation alone; no relationship was detected between grepafloxacin MICs and mutation of the QRDR of parC." | 1.30 | Relationship between mutations in parC and gyrA of clinical isolates of Streptococcus pneumoniae and resistance to ciprofloxacin and grepafloxacin. ( Johnson, AP; Stewart, BA; Woodford, N, 1999) |
| "We studied the pharmacokinetic parameters of four fluoroquinolones--ofloxacin, ciprofloxacin, temafloxacin and sparfloxacin--in a mouse model of Streptococcus pneumoniae-infected lung." | 1.28 | Pharmacokinetics of four fluoroquinolones in an animal model of infected lung. ( Azoulay-Dupuis, E; Bergogne-Bérézin, E; Pocidalo, JJ; Vallée, E, 1991) |
| "Experimental respiratory infections were established in mice by intranasal inoculation of Streptococcus pneumoniae." | 1.28 | Comparative efficacies of ciprofloxacin, amoxicillin, amoxicillin-clavulanic acid, and cefaclor against experimental Streptococcus pneumoniae respiratory infections in mice. ( Beale, AS; Gisby, J; Wightman, BJ, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (7.25) | 18.7374 |
| 1990's | 17 (24.64) | 18.2507 |
| 2000's | 36 (52.17) | 29.6817 |
| 2010's | 11 (15.94) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rozen, DE | 1 |
| McGee, L | 2 |
| Levin, BR | 1 |
| Klugman, KP | 2 |
| Odagiri, T | 1 |
| Inagaki, H | 1 |
| Nagamochi, M | 1 |
| Kitamura, T | 1 |
| Komoriya, S | 1 |
| Takahashi, H | 1 |
| Yang, R | 1 |
| Sabharwal, V | 1 |
| Shlykova, N | 1 |
| Okonkwo, OS | 1 |
| Pelton, SI | 1 |
| Kohane, DS | 1 |
| Pletz, MW | 1 |
| Michaylov, N | 1 |
| Schumacher, U | 1 |
| van der Linden, M | 1 |
| Duesberg, CB | 1 |
| Fuehner, T | 1 |
| Welte, T | 1 |
| Makarewicz, O | 1 |
| Salem, AH | 1 |
| Noreddin, AM | 1 |
| Zhang, FF | 1 |
| Zhao, CJ | 1 |
| Wang, H | 1 |
| López, E | 1 |
| Domenech, A | 1 |
| Ferrándiz, MJ | 1 |
| Frias, MJ | 1 |
| Ardanuy, C | 1 |
| Ramirez, M | 2 |
| García, E | 1 |
| Liñares, J | 1 |
| de la Campa, AG | 1 |
| Metcalf, BJ | 1 |
| Chochua, S | 1 |
| Gertz, RE | 1 |
| Li, Z | 1 |
| Walker, H | 1 |
| Tran, T | 1 |
| Hawkins, PA | 1 |
| Glennen, A | 1 |
| Lynfield, R | 1 |
| Li, Y | 1 |
| Beall, B | 1 |
| Lister, PD | 1 |
| Adam, HJ | 4 |
| Hoban, DJ | 5 |
| Gin, AS | 1 |
| Zhanel, GG | 5 |
| Antonelli, PJ | 1 |
| Winterstein, AG | 1 |
| Schultz, GS | 1 |
| Patel, SN | 1 |
| McGeer, A | 1 |
| Melano, R | 1 |
| Tyrrell, GJ | 1 |
| Green, K | 1 |
| Pillai, DR | 1 |
| Low, DE | 2 |
| Faucon, AL | 1 |
| Zamfir, O | 1 |
| Dupouët, L | 1 |
| Pruna, A | 1 |
| Pallecchi, L | 1 |
| Riccobono, E | 1 |
| Montagnani, F | 1 |
| Di Maggio, T | 1 |
| Mantengoli, E | 1 |
| Pollini, S | 1 |
| Rossolini, GM | 1 |
| Pérez-Trallero, E | 2 |
| García-Rey, C | 2 |
| Martín-Sánchez, AM | 1 |
| Aguilar, L | 3 |
| García-de-Lomas, J | 1 |
| Ruiz, J | 1 |
| Parmar, P | 1 |
| Salman, A | 1 |
| Kalavathy, CM | 1 |
| Jesudasan, CA | 1 |
| Thomas, PA | 1 |
| Bello, S | 1 |
| Torres, A | 1 |
| Hsueh, PR | 1 |
| Teng, LJ | 1 |
| Wu, TL | 1 |
| Yang, D | 1 |
| Huang, WK | 1 |
| Shyr, JM | 1 |
| Chuang, YC | 1 |
| Wan, JH | 1 |
| Yan, JJ | 1 |
| Lu, JJ | 1 |
| Wu, JJ | 1 |
| Ko, WC | 1 |
| Chang, FY | 1 |
| Yang, YC | 1 |
| Lau, YJ | 1 |
| Liu, YC | 1 |
| Lee, CM | 1 |
| Leu, HS | 1 |
| Liu, CY | 1 |
| Luh, KT | 1 |
| Garrison, MW | 1 |
| Oh, WS | 1 |
| Suh, JY | 1 |
| Song, JH | 1 |
| Ko, KS | 1 |
| Jung, SI | 1 |
| Peck, KR | 1 |
| Lee, NY | 1 |
| Yang, Y | 1 |
| Chongthaleong, A | 1 |
| Chiu, CH | 1 |
| Kamarulzaman, A | 1 |
| Parasakthi, N | 1 |
| Lalitha, MK | 1 |
| Perera, J | 1 |
| Yee, TT | 1 |
| Kumarasinghe, G | 1 |
| Carlos, CC | 1 |
| Schito, AM | 1 |
| Schito, GC | 1 |
| Etienne, M | 1 |
| Croisier, D | 1 |
| Charles, PE | 1 |
| Lequeu, C | 1 |
| Piroth, L | 1 |
| Portier, H | 1 |
| Drlica, K | 1 |
| Chavanet, P | 1 |
| Clarke, SC | 1 |
| Lawrie, D | 1 |
| Diggle, MA | 1 |
| Richter, SS | 1 |
| Heilmann, KP | 1 |
| Beekmann, SE | 1 |
| Miller, NJ | 1 |
| Rice, CL | 1 |
| Doern, GV | 1 |
| Alkorta, M | 1 |
| Giménez, MJ | 2 |
| Vicente, D | 1 |
| Sadowy, E | 1 |
| Izdebski, R | 1 |
| Skoczyńska, A | 1 |
| Gniadkowski, M | 1 |
| Hryniewicz, W | 1 |
| Fuller, JD | 1 |
| Donnenfeld, RS | 1 |
| Perry, HD | 1 |
| Solomon, R | 1 |
| Jensen, HG | 1 |
| Stein, J | 1 |
| Snyder, RW | 1 |
| Wittpenn, JR | 1 |
| Donnenfeld, ED | 1 |
| Schurek, KN | 2 |
| Decorby, MR | 1 |
| Weshnoweski, B | 1 |
| Vashisht, R | 1 |
| Karlowsky, K | 1 |
| Turnidge, J | 1 |
| Kahlmeter, G | 1 |
| Kronvall, G | 1 |
| Rivera, A | 1 |
| Rebollo, M | 1 |
| Miró, E | 1 |
| Mateo, M | 1 |
| Navarro, F | 1 |
| Gurguí, M | 1 |
| Mirelis, B | 1 |
| Coll, P | 1 |
| Nichol, KA | 2 |
| Hoban, CJ | 1 |
| Baudry, TJ | 1 |
| Laing, NM | 1 |
| Dobay, O | 1 |
| Rozgonyi, F | 1 |
| Ghidán, A | 1 |
| Matuz, M | 1 |
| Nagy, K | 1 |
| Amyes, SG | 1 |
| Bouzat, P | 1 |
| Broux, C | 1 |
| Soriano, E | 1 |
| Pavese, P | 1 |
| Croizé, J | 1 |
| Stahl, JP | 1 |
| Jacquot, C | 1 |
| Martinez-Garriga, B | 1 |
| Vinuesa, T | 1 |
| Hernandez-Borrell, J | 1 |
| Viñas, M | 1 |
| Karlowsky, JA | 2 |
| Sahin-Yilmaz, A | 1 |
| Baroody, F | 1 |
| Markaryan, A | 1 |
| Thompson, K | 1 |
| Wall, GM | 1 |
| Naclerio, R | 1 |
| Sullivan, MC | 1 |
| Cooper, BW | 1 |
| Nightingale, CH | 4 |
| Quintiliani, R | 4 |
| Lawlor, MT | 1 |
| Talbot, UM | 1 |
| Paton, AW | 1 |
| Paton, JC | 1 |
| Pfaller, MA | 1 |
| Jones, RN | 1 |
| Goldsmith, CE | 3 |
| Moore, JE | 2 |
| Murphy, PG | 2 |
| Ambler, JE | 2 |
| Lacy, MK | 2 |
| Lu, W | 1 |
| Xu, X | 1 |
| Tessier, PR | 1 |
| Nicolau, DP | 3 |
| Tarasi, A | 1 |
| Capone, A | 1 |
| Tarasi, D | 1 |
| Cassone, M | 1 |
| Bianco, G | 1 |
| Venditti, M | 1 |
| Onyeji, CO | 1 |
| Bui, KQ | 1 |
| Owens, RC | 1 |
| Heaton, VJ | 1 |
| Fisher, LM | 1 |
| Banevicius, MA | 1 |
| Stewart, BA | 1 |
| Johnson, AP | 2 |
| Woodford, N | 1 |
| Hershberger, E | 1 |
| Rybak, MJ | 1 |
| Fuentes, F | 1 |
| Marco, F | 1 |
| Alou, L | 2 |
| Prieto, J | 2 |
| Karcic, AA | 1 |
| Khan, FA | 1 |
| Warner, M | 1 |
| George, RC | 1 |
| Livermore, DM | 1 |
| Walters, M | 1 |
| Laing, N | 1 |
| Rubinstein, E | 1 |
| Diamantstein, L | 1 |
| Yoseph, G | 1 |
| Gruzman, G | 1 |
| Rubinovitch, B | 1 |
| Barzilai, A | 1 |
| Keller, N | 1 |
| Nealy, L | 1 |
| Sahm, DF | 1 |
| Thornsberry, C | 1 |
| Jones, ME | 1 |
| de Lencastre, H | 1 |
| Bertone, C | 1 |
| Rivera, F | 1 |
| Avallone, F | 1 |
| Urgelli, S | 1 |
| Maniscalco, P | 1 |
| White, RL | 1 |
| Enzweiler, KA | 1 |
| Friedrich, LV | 1 |
| Wagner, D | 1 |
| Hoban, D | 1 |
| Bosso, JA | 1 |
| Vallée, E | 1 |
| Azoulay-Dupuis, E | 1 |
| Pocidalo, JJ | 1 |
| Bergogne-Bérézin, E | 1 |
| Salvi, A | 1 |
| Rossi, M | 1 |
| Balestrieri, GP | 1 |
| di Stefano, O | 1 |
| Baratto, G | 1 |
| Giustina, G | 1 |
| Gisby, J | 1 |
| Wightman, BJ | 1 |
| Beale, AS | 1 |
| Albrecht, HA | 1 |
| Beskid, G | 1 |
| Chan, KK | 1 |
| Christenson, JG | 1 |
| Cleeland, R | 1 |
| Deitcher, KH | 1 |
| Georgopapadakou, NH | 1 |
| Keith, DD | 1 |
| Pruess, DL | 1 |
| Sepinwall, J | 1 |
| Righter, J | 1 |
| Frieden, TR | 1 |
| Mangi, RJ | 1 |
| Cooper, B | 1 |
| Lawlor, M | 1 |
| Honeybourne, D | 1 |
| Wise, R | 1 |
| Andrews, JM | 1 |
| Davies, BI | 2 |
| Maesen, FP | 2 |
| Teengs, JP | 1 |
| Baur, C | 2 |
| Hoogkamp-Korstanje, JA | 1 |
| Klein, SJ | 1 |
3 reviews available for ciprofloxacin and Pneumococcal Infections
| Article | Year |
|---|---|
Levofloxacin, a broad spectrum anti-infective: from Streptococcus pneumoniae to Pseudomonas aeruginosa.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Humans; Italy; Levofloxacin; Micro | 2004 |
A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Female; F | 2005 |
Pneumococcal septic arthritis of the shoulder. Case report and literature review.
Topics: Aged; Anti-Bacterial Agents; Arthritis, Infectious; Ciprofloxacin; Drug Therapy, Combination; Humans | 2002 |
66 other studies available for ciprofloxacin and Pneumococcal Infections
| Article | Year |
|---|---|
Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
Topics: DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Se | 2007 |
Design, Synthesis, and Biological Evaluation of Novel 7-[(3 aS,7 aS)-3 a-Aminohexahydropyrano[3,4- c]pyrrol-2(3 H)-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens.
Topics: Animals; Anti-Bacterial Agents; Drug Design; Drug Evaluation, Preclinical; Drug Resistance, Bacteria | 2018 |
Treatment of Streptococcus pneumoniae otitis media in a chinchilla model by transtympanic delivery of antibiotics.
Topics: Animals; Anti-Bacterial Agents; Chinchilla; Ciprofloxacin; Disease Models, Animal; Dose-Response Rel | 2018 |
Antihypertensives suppress the emergence of fluoroquinolone-resistant mutants in pneumococci: an in vitro study.
Topics: Anti-Bacterial Agents; Antihypertensive Agents; Ciprofloxacin; DNA, Bacterial; Drug Resistance, Bact | 2013 |
Moxifloxacin in lower respiratory tract infections: in silico simulation of different bacterial resistance and drug exposure scenarios.
Topics: Area Under Curve; Bronchopneumonia; Ciprofloxacin; Community-Acquired Infections; Drug Resistance, B | 2014 |
[Fluoroquinolone resistance determining region mutation in Streptococcus pneumonia isolates].
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Child; Child, Preschool; Ciprofloxacin; DNA Gyrase; | 2013 |
Induction of prophages by fluoroquinolones in Streptococcus pneumoniae: implications for emergence of resistance in genetically-related clones.
Topics: Blotting, Southern; Chronic Disease; Ciprofloxacin; Disease Progression; Drug Resistance, Bacterial; | 2014 |
Using whole genome sequencing to identify resistance determinants and predict antimicrobial resistance phenotypes for year 2015 invasive pneumococcal disease isolates recovered in the United States.
Topics: Anti-Bacterial Agents; Chloramphenicol; Ciprofloxacin; Clindamycin; Drug Resistance, Multiple, Bacte | 2016 |
Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; | 2008 |
Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997-2006.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Canada; Child; Child, Preschool; | 2009 |
Topical dexamethasone and tympanic membrane perforation healing in otitis media: a short-term study.
Topics: Administration, Cutaneous; Animals; Anti-Infective Agents; Chi-Square Distribution; Chinchilla; Cipr | 2010 |
Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada.
Topics: Anti-Bacterial Agents; Aza Compounds; Binding Sites; Canada; Ciprofloxacin; DNA Gyrase; DNA Topoisom | 2011 |
[Streptococcus pneumonia infection and positive blood culture with Francisella tularensis, in a renal transplant recipient].
Topics: Aged; Anti-Bacterial Agents; Bacteriological Techniques; Blood; Ceftriaxone; Ciprofloxacin; Drug The | 2011 |
Antipneumococcal activity of ulifloxacin compared to levofloxacin and ciprofloxacin.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Disk Diffusion Antimicrobial Tests; Drug Resistance, Multiple, | 2011 |
Activities of six different quinolones against clinical respiratory isolates of Streptococcus pneumoniae with reduced susceptibility to ciprofloxacin in Spain.
Topics: Anti-Infective Agents; Ciprofloxacin; Data Collection; Drug Resistance, Microbial; Humans; Pneumococ | 2002 |
Pneumococcal keratitis: a clinical profile.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Cornea; Corneal Ulcer; Dacryocystitis; Dacryocystorhino | 2003 |
[Pneumococcus and quinolone resistance].
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Child, Preschool; Ciproflo | 2003 |
Telithromycin- and fluoroquinolone-resistant Streptococcus pneumoniae in Taiwan with high prevalence of resistance to macrolides and beta-lactams: SMART program 2001 data.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactam Resistance; Ciprofloxacin; Erythrom | 2003 |
Comparative antimicrobial activity of levofloxacin and ciprofloxacin against Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; Area Under Curve; Ciprofloxacin; Humans; Kinetics; Levofloxacin; Microbial Se | 2003 |
Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae from Asian countries: ANSORP study.
Topics: Anti-Bacterial Agents; Asia; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA, Bacterial; Drug R | 2004 |
Effect of low-level resistance on subsequent enrichment of fluoroquinolone-resistant Streptococcus pneumoniae in rabbits.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; DNA Topoisomerase IV; Drug Resistance, | 2004 |
Genetic relatedness of antibiotic-resistant pneumococci isolated during case clusters.
Topics: Anti-Bacterial Agents; Bacterial Typing Techniques; Blood; Ciprofloxacin; DNA, Bacterial; Drug Resis | 2004 |
The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations.
Topics: Anti-Bacterial Agents; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; | 2005 |
In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Disease Models, Animal; DNA Gyrase; DN | 2005 |
High genetic diversity of ciprofloxacin-nonsusceptible isolates of Streptococcus pneumoniae in Poland.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field | 2005 |
A comparison of gatifloxacin to ciprofloxacin in the prophylaxis of Streptococcus pneumoniae in rabbits in a LASIK model.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Cornea; Disease Models, Animal; Eye Infections, Bacte | 2006 |
Comparative in vitro activity of PGE 9262932 and fluoroquinolones against Canadian clinical Streptococcus pneumoniae isolates, including molecularly characterized ciprofloxacin-resistant isolates.
Topics: Anti-Bacterial Agents; Canada; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Genotype | 2006 |
Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values.
Topics: Anti-Infective Agents; Bacteria; Ciprofloxacin; Drug Resistance, Bacterial; Epidemiologic Methods; H | 2006 |
Superantigen gene profile, emm type and antibiotic resistance genes among group A streptococcal isolates from Barcelona, Spain.
Topics: Alleles; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Drug Resistance; Erythromycin; | 2006 |
Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aza Compounds; Bacterial Proteins; Canada; | 2007 |
The first steps towards fluoroquinolone resistance in Hungarian pneumococci.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Proteins; Carbonyl Cyanide m-Chlorophenyl Hydrazone; | 2006 |
[Streptococcus pneumoniae cellulitis in a diabetic patient].
Topics: Aged; Ceftriaxone; Cellulitis; Ciprofloxacin; Diabetes Complications; Humans; Male; Metronidazole; M | 2007 |
The contribution of efflux pumps to quinolone resistance in Streptococcus pneumoniae clinical isolates.
Topics: Bacterial Proteins; Ciprofloxacin; Drug Resistance, Bacterial; Genes, Bacterial; Humans; Membrane Tr | 2007 |
Increasing genetic relatedness of ciprofloxacin-resistant Streptococcus pneumoniae isolated in Canada from 1997 to 2005.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Canada; Child; Ciprofloxacin; DNA Gyrase; DNA | 2008 |
Effect of topical ciprofloxacin/dexamethasone or dexamethasone alone on acute Streptococcus pneumoniae rhinosinusitis in mice.
Topics: Administration, Topical; Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Dex | 2008 |
Evaluation of the efficacy of ciprofloxacin against Streptococcus pneumoniae by using a mouse protection model.
Topics: Animals; Ciprofloxacin; Half-Life; Mice; Microbial Sensitivity Tests; Penicillin G; Pneumococcal Inf | 1993 |
Uptake of Streptococcus pneumoniae by respiratory epithelial cells.
Topics: Bacterial Adhesion; Bacterial Capsules; Bacterial Proteins; Cells, Cultured; Chloramphenicol; Ciprof | 1996 |
Comparative antistreptococcal activity of two newer fluoroquinolones, levofloxacin and sparfloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Humans; In Vitro | 1997 |
Pneumococcal resistance in the UK.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Cephalosporins; Chloramphenicol; Ciprofloxacin; Drug R | 1997 |
Increased incidence of ciprofloxacin resistance in penicillin-resistant pneumococci in Northern Ireland.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Drug Resistance, Multiple; Humans; | 1998 |
Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection.
Topics: Ampicillin; Ampicillin Resistance; Anti-Infective Agents; Ciprofloxacin; Culture Media; Drug Resista | 1999 |
Comparative in-vitro activity of moxifloxacin, penicillin, ceftriaxone and ciprofloxacin against pneumococci isolated from meningitis.
Topics: Anti-Bacterial Agents; Aza Compounds; Ceftriaxone; Ciprofloxacin; Fluoroquinolones; Humans; Meningit | 1999 |
Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia.
Topics: Acute Kidney Injury; Administration, Cutaneous; Animals; Anti-Infective Agents; Bacteremia; Ciproflo | 1999 |
Activity of gemifloxacin against penicillin- and ciprofloxacin-resistant Streptococcus pneumoniae displaying topoisomerase- and efflux-mediated resistance mechanisms.
Topics: Anti-Infective Agents; Ciprofloxacin; DNA Topoisomerases, Type I; Drug Resistance, Microbial; Fluoro | 1999 |
Protective effect of trovafloxacin, ciprofloxacin and ampicillin against Streptococcus pneumoniae in a murine sepsis model.
Topics: Ampicillin; Animals; Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Mice; Naphthyridines; P | 1999 |
Relationship between mutations in parC and gyrA of clinical isolates of Streptococcus pneumoniae and resistance to ciprofloxacin and grepafloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Deoxyribonucleases, Type II Site-Specific; DNA Gyrase; DNA Top | 1999 |
Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model.
Topics: Anti-Infective Agents; Blood Coagulation; Ciprofloxacin; Fibrin; Fluoroquinolones; Gatifloxacin; Hum | 2000 |
In vitro susceptibility to gemifloxacin and trovafloxacin of Streptococcus pneumoniae strains exhibiting decreased susceptibility to ciprofloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Gemifloxacin; Hu | 2000 |
Ciprofloxacin vs. the pneumococcus.
Topics: Anti-Infective Agents; Ciprofloxacin; Humans; Pneumococcal Infections; Respiratory Tract Infections; | 2000 |
Activity of moxifloxacin against clinical isolates of Streptococcus pneumoniae from England and Wales.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Microbial; England; Fluoroquin | 2001 |
In vitro pharmacodynamic modelling simulating free serum concentrations of fluoroquinolones against multidrug-resistant Streptococcus pneumoniae.
Topics: Administration, Oral; Anti-Infective Agents; Ciprofloxacin; Computer Simulation; Drug Resistance, Mi | 2001 |
The effect of albumin, globulin, pus and dead bacteria in aerobic and anaerobic conditions on the antibacterial activity of moxifloxacin, trovafloxacin and ciprofloxacin against Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli.
Topics: Albumins; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Escherichia coli; Escherichia coli In | 2000 |
Trends in ciprofloxacin nonsusceptibility and levofloxacin resistance among Streptococcus pneumoniae isolates in North America.
Topics: Anti-Infective Agents; Ciprofloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; North Ameri | 2001 |
Streptococcus pneumoniae isolates with reduced susceptibility to ciprofloxacin in Spain: clonal diversity and appearance of ciprofloxacin-resistant epidemic clones.
Topics: Anti-Infective Agents; Ciprofloxacin; DNA, Bacterial; Drug Resistance, Microbial; Electrophoresis, G | 2001 |
Comparative activity of gatifloxacin and other antibiotics against 4009 clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Ceftriaxone; Ch | 2002 |
Pharmacokinetics of four fluoroquinolones in an animal model of infected lung.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Disease Models, Animal; Fluoroquinolones; Lung Diseas | 1991 |
Septic polyarthritis in chronic tophaceous gout.
Topics: Ampicillin; Arthritis, Infectious; Cefotaxime; Ciprofloxacin; Gout; Humans; Male; Middle Aged; Pneum | 1991 |
Comparative efficacies of ciprofloxacin, amoxicillin, amoxicillin-clavulanic acid, and cefaclor against experimental Streptococcus pneumoniae respiratory infections in mice.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cefaclor; Ciprofloxacin; Cla | 1991 |
Cephalosporin 3'-quinolone esters with a dual mode of action.
Topics: Animals; Anti-Infective Agents; Cefotaxime; Cephalosporins; Chemical Phenomena; Chemistry; Ciproflox | 1990 |
Pneumococcal meningitis during intravenous ciprofloxacin therapy.
Topics: Aged; Ciprofloxacin; Female; Humans; Meningitis, Pneumococcal; Microbial Sensitivity Tests; Pneumoco | 1990 |
Inappropriate use of oral ciprofloxacin.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Cellulitis; Ciprofloxacin; Drug Utilization; F | 1990 |
Pneumococcal bacteremia during ciprofloxacin therapy for pneumococcal pneumonia.
Topics: Ciprofloxacin; Humans; Male; Middle Aged; Pneumococcal Infections; Pneumonia, Pneumococcal; Sepsis | 1989 |
Ciprofloxacin penetration into lungs.
Topics: Bronchi; Ciprofloxacin; Humans; Pneumococcal Infections | 1987 |
[New oral quinolone compounds in chronic bronchitis].
Topics: Administration, Oral; Anti-Bacterial Agents; Bacterial Infections; Bronchitis; Chronic Disease; Cipr | 1986 |
Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis.
Topics: Aged; Anti-Bacterial Agents; Bacterial Infections; Bronchitis; Chronic Disease; Ciprofloxacin; Drug | 1986 |
Treatment of acute exacerbations of chronic bronchitis with ciprofloxacin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Bronchitis; Ciprofloxacin; Female; | 1987 |